Kamada Raised Guidance and Quietly Retired Its Science Story
A record quarter funded entirely by products already on the shelf — while the pipeline that once dominated the Q&A stops appearing on the call at all
KMDA.TA · Earnings Call · 2026-11-09
Kamada Raised Guidance and Quietly Retired Its Science Story
The cleanest quarter Kamada has ever printed
There is no ambiguity in the numbers. Nine-month revenue of $152.2 million, up 12%; adjusted EBITDA of $40.9 million, up 20% and a 27% margin of revenue; net income of $21.4 million, up 29%. The third quarter alone delivered $52 million of revenue (+11%), $15.2 million of adjusted EBITDA at a 29% margin and net income up 51%. Cash from operations for the nine months nearly doubled to $37.6 million from $17.9 million. Management lifted full-year revenue guidance to $205–208 million and adjusted EBITDA to $52–54 million, midpoints implying 14% and 26% growth — the second raise of the year, off a starting range of $200–205 million. And yet the sentence that carries the most information is not the raise. It is the qualifier attached to it: “the significant growth we are currently experiencing is driven solely by our existing commercial product portfolio” — Amir London, Chief Executive Officer · 2026-11-09. That is a company admitting, in the same breath as a guidance hike, that none of its three forward-looking levers — M&A, plasma vertical integration, the inhaled AAT program — has contributed a dollar. The organic machine at Kamada is excellent. The rest of the story remains a slide.KEDRAB is a genuine, company-specific inflection
This is the real news, and it has almost nothing to do with the rest of the market. End-user utilization of the anti-rabies immunoglobulin KEDRAB accelerated after a CDC health advisory, and management now pegs U.S. share at no less than half the market: “We believe that we are with at least 50% market share” — Amir London, Chief Executive Officer · 2026-11-09. Kedrion is ordering above its contractual floor, the supply agreement runs to end-2031, and Kamada says it holds both inventory and manufacturing capacity for further growth. Management explicitly rejects the one-time framing — 2026 demand is a level shift, not a bolus. Contrast that with the August 2025 call, when KEDRAB was the flat line in the portfolio: “KEDRAB and CYTOGAM are performing according to our expectations... the numbers are similar to 2024 numbers” — Amir London, Chief Executive Officer · 2025-08-13. Fifteen months later KEDRAB is the lead growth driver and the minimum commitment from Kedrion has become a floor rather than a ceiling. That is a real change of state in the highest-margin part of the P&L. Why it matters beyond Kamada: nobody else is talking about it. Scanning this week's cohort of reporters, no peer raised rabies, post-exposure prophylaxis, or hyperimmune demand — the nearest plasma-adjacent chatter is Ig product competition at ADMA. The market's own top keywords this quarter are macro noise (Fed path, tariffs, supply chains). Kamada's signal is idiosyncratic: three products globally meet FDA or EMA standards in this niche, and one of them just got a public-health tailwind.What management stopped talking about
The most striking feature of the Q3 call is silence. Search the prepared remarks and the Q&A for the inhaled AAT program — the Phase 3 InnovAATe study that was, for two years, the single most-discussed asset in Kamada's story — and you find nothing. No enrollment update, no data timing, no analyst question. The same for the SHIELD study and the late-onset CMV work that drove the entire CYTOGAM narrative in 2024 and 2025: CYTOGAM now earns exactly one passing clause in prepared remarks, a "comprehensive post-marketing research program." That absence is not cosmetic, because Kamada made a specific, dated promise last November:An interim futility analysis on a pivotal efficacy endpoint in alpha-1 antitrypsin deficiency was supposed to be a binary, publicly announced readout before the end of 2025. A year later, the topic is not on the agenda and no analyst asked. Either it read through quietly and the trial is grinding toward a 2029 top-line, or it is shelved. The call does not say, and that gap — not the earnings beat — is the actual informational asymmetry in this report.It will be conducted by the end of the year. Results will be publicly shared through a press release... This is going to be a go, no-go futility analysis.
The two deferrals: integration and M&A
Investors have been told for several quarters that proprietary plasma would lift gross margin. In March, the CFO put a date on it: “in terms of specialty plasma, we expect now to continue ramping up our collection, and this will start to have effect on our gross profit starting 2027 and beyond” — Amir London, Chief Executive Officer · 2026-03-11. In August it was still "yet to come." In November it is unchanged:The gross-margin math confirms the deferral: nine-month gross margin was 43% versus 44% a year earlier — slightly down, not up. The Q3 improvement to 45% is attributed to product and market mix, not to vertical integration. So the $50 million, three-year source-plasma contract (initial sales land this quarter) is real revenue but not yet a margin story. Meanwhile the M&A promise is now in at least its third revision. In March: “we are optimistic that we'll be able to secure such a transaction already in 2026” — Amir London, Chief Executive Officer · 2026-03-11. In November: “We do have opportunities, and we believe that, hopefully, in the near term, we already will have some good news to report” — Amir London, Chief Executive Officer · 2026-11-09. Same language, later calendar. What management has done instead is return cash: approximately $32.3 million of dividends in 2026 ($24.2 million paid, plus a freshly declared $0.14 per share, roughly $8 million, payable in Q4) against a market capitalization near $429 million. That is about 7.5% of the equity handed back in a single year — an unusual choice for a $200 million-revenue company still promising transformative acquisitions, and arguably the clearest statement of where the board thinks the marginal dollar earns its best return.So plasma, normal source plasma sales, or specialty plasma utilization in our own manufacturing is not yet part of our P&L... any additional improvements in top-line and profitability as a result of our own vertical integration is yet to come, and yet to be demonstrated or part of our P&L.